1.25 / AMA PRA Category 1 CreditsTM 1.25 / CPD Credits
Provided by Haymarket Medical Education in collaboration with MIMS and GP MIMS
Supported by an educational grant from Novo Nordisk A/S
Poor glycemic control in diabetes is a global problem, despite the availability of numerous glucose-lowering therapies and clear guidelines for patients with type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM) management. A failure to intensify treatment in a timely and appropriate manner leads to not only an inability to reach target A1C goals, but also to an increased risk of cardiovascular disease (CVD) morbidity and mortality associated with the disease. Recent studies implicate elevated postprandial glucose (PPG) as an important driver of poor glycemic control.
A disincentive for clinicians to consider intensifying treatment for T2DM patients who require insulin is a fear of inducing hypoglycemia and its attendant complications and impact on patient adherence. This activity is designed to provide insight into a new-generation of rapid-acting insulins and basal insulin coformulations, which have been shown to improve fasting and PPG control and to mitigate the hypoglycemic and CVD effects in a substantial proportion of patients who now are failing to reach optimal A1C targets.
Endocrinologists, internists, and primary care clinicians (ie, family medicine/family practice physicians, nurse practitioners [NPs], and physician assistants [PAs]) who care for patients with diabetes.
At the conclusion of this activity, participants should be better able to:
Recognize and address clinical inertia to ensure timely intensification of treatment as needed in individuals with diabetes
Apply an understanding of the prevalence and consequences of hypoglycemia when individualizing treatment plans for patients with diabetes mellitus
Assess data on the safety and efficacy of new and emerging insulins and insulin combinations to better inform treatment planning
Identify patients who may benefit from rapid-acting insulin to optimize postprandial glucose (PPG) control
Conflict Of Interest Disclosure Policy
In accordance with the ACCME Standards for Commercial Support, HME requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. HME resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational activities.
Furthermore, HME seeks to verify that all scientific research referred to, reported, or used in a continuing medical education (CME) activity conforms to the generally accepted standards of experimental design, data collection, and analysis. HME is committed to providing its learners with high-quality CME activities that promote improvements in healthcare and not those of a commercial interest.
Bruce W. Bode, MD, FACE – Moderator Atlanta Diabetes Associates Clinical Associate Professor Emory University Atlanta, GA, USA
Dr. Bode is a consultant for and receives research grant funds from Insulet Corporation, Medtronic, Novo Nordisk, and Sanofi. Dr. Bode is on the speakers’ bureaus for Insulet Corporation, Lilly, Medtronic, Novo Nordisk, and Sanofi.
Francesc Xavier Cos Claramunt, MD Associate Professor and Chairman Primary Care Diabetes Europe Universitat Autonoma de Barcelona Jordi Gol Institute for Research in Primary Care Barcelona, Spain
Dr. Cos Claramunt is a consultant for AstraZeneca, Boehringer Ingelheim, Eli Lilly and Co., Novartis Pharmaceuticals, Roche, Sanofi, and Sanofi Pasteur. His is on the speakers’ bureaus for AstraZeneca, Boehringer Ingelheim, Eli Lilly and Co., Novartis Pharmaceuticals, Merck Sharp & Dohme Corp., Roche, Sanofi, and Sanofi Pasteur. Dr. Cos Claramunt receives research grant funds from AstraZeneca and Novartis Pharmaceuticals.
Stefano Del Prato, MD Professor of Endocrinology Chief, Section of Diabetes and Metabolic Diseases Department of Clinical and Experimental Medicine University of Pisa Pisa, Italy
Dr. Del Prato is a consultant for Abbott, AstraZeneca, Boehringer Ingelheim, Eli Lilly and Co., GlaxoSmithKline, Laboratoires Servier, Merck & Co., Inc., Novartis Pharmaceuticals, Novo Nordisk, Sanofi, and Takeda Pharmaceuticals. He receives research grant funds from AstraZeneca, Boehringer Ingelheim, Merck & Co., Inc., and Novartis Pharmaceuticals.
Kamlesh Khunti, MD, PhD, FRCP, FRCGP, FMedSci Professor and Head, Primary Care Diabetes and Vascular Medicine Department Diabetes Research Centre University of Leicester Leicester, UK
Dr. Khunti is a consultant for Amgen, AstraZeneca, Bayer, Berlin-Chemie AG/Menarini Group, Eli Lilly and Co., Merck Sharp & Dohme Corp., NAPP Pharmaceuticals Ltd., Novartis Pharmaceuticals, Novo Nordisk, Roche, Sanofi-Aventis, and Laboratoires Servier. He is on the speakers’ bureaus for AstraZeneca, Bayer, Berlin-Chemie AG/Menarini Group, Eli Lilly and Co., Merck Sharp & Dohme Corp., NAPP Pharmaceuticals Ltd., Novartis Pharmaceuticals, Novo Nordisk, Roche, and Sanofi-Aventis. Dr. Khunti receives research grant funds and is on the advisory boards for Eli Lilly and Co., Novo Nordisk, and Sanofi-Aventis.
Andreas Liebl, MD Medical Director, Department for Internal Medicine Center for Diabetes and Metabolism Fachklinik Bad Heilbrunn Bad Heilbrunn, Germany
Dr. Liebl is on the speakers’ bureaus for AstraZeneca, Boehringer Ingelheim, Eli Lilly and Co., Medtronic, Merck Sharp & Dohme Corp., Novo Nordisk, Roche, and Sanofi. Dr. Liebl is a consultant for Becton Dickinson, Boehringer Ingelheim, Eli Lilly and Co., Merck Sharp & Dohme Corp., Novo Nordisk, and Roche.
Yves Reznik, MD University Professor, Hospital Practitioner Head, Department of Diabetes and Endocrinology CHU Côte de Nacre Caen, France
Dr. Reznik has no relevant financial relationships to disclose.
Accredited Provider Disclosure
Haymarket Medical Education staff involved in the planning and content review of this activity have no relevant financial relationships to disclose.
AMA PRA Category 1 Credit(s)TM
Haymarket Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Haymarket Medical Education designates this enduring material for a maximum of 1.25 AMA PRA Category 1 CreditsTM . Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Additional Credit Information
CPD credit information for UK healthcare professionals This activity has been produced by the Haymarket Medical Education editorial team, under the guidance of the MIMS Learning expert faculty. A recommended learning credit value of 1.25 CPD credits (1 hour 15 minutes of learning activity) is provided to assist the participant.
This credit value is in line with the recommendations of the Royal College of General Practitioners.
Physician Assistant Continuing Education AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 CreditTM from organizations accredited by ACCME or a recognized state medical society. PAs may receive a maximum of 1.00 Category 1 Credit for completing this activity.
Nurse Practitioner Continuing Education The American Academy of Nurse Practitioners Certification Program (AANPCP) accepts certificates of participation for educational activities certified for AMA PRA Category 1 CreditTM from organizations accredited by ACCME. Individuals are responsible for checking with the AANPCP for further guidelines.
This activity is awarded 1.00 contact hour.
Disclosure of Unlabeled Use
This activity may include presentations in which presenters may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet approved by the European Medicine Agency (EMA). Participants should note that the use of products outside currently EMA-approved labeling should be considered experimental and are advised to consult current prescribing information for EMA-approved indications.
Faculty, speakers, presenters, authors, activity medical directors, and moderators are required to disclose to the learners when products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not EMA-approved) as well as any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of Haymarket Medical Education or Novo Nordisk A/S. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
To obtain credit, a score of 70% or better on the post-test is required. This activity is offered at no cost to participants. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your credit certificate. Your online certificate will be saved on myCME within your Profile/CME History, which you can access at any time.